Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolic Autism Prediction (MAP) Study

NCT04672967 is registered in ClinicalTrials.gov with BioROSA Technologies Inc as lead sponsor.

NCT NCT04672967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolic Autism Prediction (MAP) Study
Lead sponsor
BioROSA Technologies Inc
Phase
Observational
Overall status
Unknown status
Start date
November 3, 2021
Completion date
October 31, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder, developmental delay